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ABSTRACT 
CORRELATION OF THE SIGNS AND SYMPTOMS OF UTERINE 
LEIOMYOMAS WITH THE FINDINGS ON MAGNETIC RESONANCE 
IMAGING STUDIE5. 
Symphorosa Magdaleine Williams 
1991 
This study was designed to investigate any correlation between the 
symptoms and signs of uterine leiomyomas and magnetic resonance imaging 
(MRi) findings. The symptoms and signs reported at each visit were recorded 
from a review of the clinical charts of 45 patients. 1 14MR1 studies, 93 of 
which were performed within 0-30 days, and 16 of which were performed 
within 30-51 days of the corresponding clinical visit, were reviewed by an 
investigator, biinded to the clinical data. Total uterine volume, total 
leiomyoma volume, and the uterine and leiomyoma MR! characteristics were 
assessed. Thirty-one patients, with a total of 47 MRi studies, received 
leuproiide acetate (LA) during the period of review. These were examined as 
a separate group, and compared with the “no drug" group. Junctional zone 
(JZ) disruption did not correlate with the presence of menorrhagia or 
metrorrhagia (p > 0.05) in either patient group. LA decreased the Incidence 
of menorrhagia (p < 0.0005), but had no effect on metrorrhagia (p > 0.05). JZ 
disruption did not correlate with spontaneous abortion or Infertility (p > 
0.1). The leiomyoma location (uterine body, fundus, cervix, broad ligament, 
multiple) did not affect the incidence of pressure (p > 0.1), abdominal/pelvic 

(A/'P) pain (p > 0.1)., Pack pain (p > 0.1), or infertility (p > 0.5). LA decreased 
the incidence of pressure only in patients with leiomyomas in the uterine 
body (p < 0.05). The leiomyoma type (submucosal, intramural, subserosa!) did 
not affect the incidence of infertility (p > 0.05) or spontaneous abortion (p > 
0.5). It did not affect dysmenorrhea in LA treated patients (p > 0.55, but 
intramural leiomyomas were associated with dysmenorrhea in the no drug 
group (p < 0.005). Submucosal and intramural tumors in patients with no 
drug treatment were also associated with dysmenorrhea, when compared 
with LA treated patients (p < 0.005). Leiomyoma degeneration was dependent 
on the tumor volume. Smaller tumors had less degeneration while the larger 
tumors had more carneous and non-specific degenerative changes (p < 
0.005). LA had no effect on the incidence of degeneration. A/P pain was 
associated with carneous leiomyomas in patients with no drug treatment (p 
< 0.05). There was no association between A/P pain or pressure and total 
uterine volume (p > 0.1), but LA decreased the incidence of pain in patients 
with uterine volumes less than 600 cc (p < 0.005). Uterine non-leiomyoma 
volumes were not associated with spontaneous abortion or infertility (p > 
0 5). We conclude that most symptoms that have always been attributed to 
Individual characteristics of the leiomyomas cannot be directly explained by 
them. The only statistically significant relationships occurred between 
degeneration and tumor size, and dysmenorrhea and intramural tumors. The 
effect of LA in alleviating patient symptoms is again confirmed. 
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1. INTRODUCTION 
I. UTERINE LEIOMYOMAS 
A. Epidemiology & Etiology 
Uterine leiomyomas, also known as fibroids, fibromas, or 
fibromyomas (42), are benign smooth muscle tumors of the uterus.They are 
the most common pelvic tumors in women, occurring in one out of four to 
five women of reproductive age (9). They occur more frequently in women 
over thirty-five years of age (42), and they are responsible for at least 
one-third of all gynecological admissions (50). Leiomyomas are also more 
common in Black women than in White women (42). The reason for this 
racial difference in incidence is not known. 
The etiology of these tumors is still not clearly understood. Various 
theories include the probability that i. they arise from groups of 
persistent embryonic cells (42), ii. they arise from the smooth muscle 
layers of blood vessels in the myometrium (42), iii. they arise from a 
single neoplastic parent smooth muscle cell in the myometrium (9). This 
latter theory is supported by the evidence presented by Townsend et al. 
who found that cells in each individual leiomyoma had identical glucose- 
6-phosphate dehydrogenase (electrophoretically), although this enzyme 
was different in other leiomyomas within the same uterus ( 58 ). Although 
the initial etiology of these tumors is not clearly defined, one generally 
accepted factor in the growth of leiomyomas is the effect of estrogen. 
Leiomyomas tend to occur in women of reproductive age; they rarely occur 

before menarche, and usually regress after menopause. They also 
proliferate during pregnancy, and with the use of birth-control pills, when 
serum estrogen levels are high. (42). Wilson et al. and Tamaya et a!., in 
separate studies, demonstrated a higher concentration of estrogen 
receptors in leiornyomatous tissue than in adjoining myometrium in the 
same patient (60, 56 ). Other hormones, such as growth hormone and human 
placental lactogen have been implicated in a probable synergistic effect 
with estrogen on the tumor proliferation (9). This may explain the 
increased sensitivity of leiornyomatous tissue to estrogen, and the rapid 
growth observed in hyperestrogenic states. There are, however, several 
other factors, currently unknown, which contribute to the varying rates of 
growth of leiomyomas in different women. Additional studies will be 
needed to further clarify the etiology and development of leiomyomas. 
B. Histopathologv 
Leiomyomas have three main classifications, depending on the layer 
of the uterus they originate in. They are called subserosal when they arise 
from the myometrium and grow directly beneath the uterine serosa, 
projecting into the pelvic cavity (42). Subserosal leiomyomas can become 
pedunculated with increased growth and form a migratory leiomyoma (50). 
They may remain attached to the uterus by a pedicle, or may attach to 
adjacent viscera, peritoneum, or omentum. In the latter case, the 
subserosal leiomyoma may lose its primary blood supply from the uterus, 
develop a secondary blood supply from its new attachment, and is then 
classified as a parasitic leiomyoma, intraligamentous leiomyomas occur 

when the subserosal leiomyoma grows into the broad ligament. Intramural 
leiomyomas, the most frequent type of leiomyomas, originate in the 
myometrium, and while they may impinge on the uterine serosa or mucosa, 
the bulk of the leiomyoma remains in the myometrium. These can also 
enlarge, and distort the uterine cavity or the outer uterine surface. 
Submucosal leiomyomas arise in the myometrium directly beneath the 
endometrium. These may also distort the uterine cavity. They also 
occasionally become pedunculated, and can then protrude into the cervix 
and vaginal canal where they are prone to infection (42). 
Leiomyomas occur most frequently within the uterine corpus (42, 
50). They less frequently occur in the lower uterine segment, the cervical 
region (50), the isthmus and the cornual regions of the uterus. They can 
occur singly, but are often multiple, ranging in size from barely visible 
"seedlings" of one centimeter or less, to large masses (42, 50), weighing 
as much as 147 lbs (42). They are firm masses, distinct from the 
surrounding myometrium. The leiomyomas do not have true capsules, but 
are covered by a pseudocapsule, formed by compression of the surrounding 
myometrium (42). Gross pathological inspection shows a characteristic 
whorled pattern of smooth muscle bundles (42, 50). Histologically, the 
smooth muscle cells of the leiomyomas resemble those of the normal 
myometrium, without increased mitotic figures or anaplastic changes 
(50). There is fibrous connective tissue interspersed between the smooth 
muscle bundles with one or more blood vessels providing nutrients to the 
tumors. 
Leiomyomas may undergo various degenerative changes. These are 
often associated with a relative decrease in blood supply, which usually 
occurs with a rapid increase in the growth of the tumors, particularly in 
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pregnancy, when there is mechanical disruption of the blood vessels, or 
degenerative changes may occur with menopause. (42). These changes 
consist of hyaline, cystic, fatty, carneous, or calcific degeneration. 
Hyaline degeneration is the most common type of degenerative change, and 
occurs in even small leiomyomas (42). Persaud et al. found hyaline 
degeneration in 63% of the 195 leiomyomas that had degenerative changes 
(45). The consistency of the tumor changes and becomes softer. On gross 
examination, the degenerated areas are pale, homogeneous, and lack the 
characteristic whorled appearance. Microscopically, hyaline connective 
tissue replaces the smooth muscle cells, and the affected regions appear 
amorphous and pinkish-red (45). Hyalinization can further degenerate into 
liquefied areas (42,45), which are also visible grossly - cystic 
degeneration. These cysts lack an epithelium, and may contain colorless or 
bloodstained fluid. Myxomatous and mucoid changes can also result in 
cystic degeneration. Fatty degeneration occurs rarely, and is also 
associated with hyaline changes. It is characterized by small vacuolated 
fat-containing cells within the tumors (45). Carneous (red) degeneration is 
believed to occur in about 8% of leiomyomas complicating pregnancy. 
Aseptic necrosis occurs, followed by hemorrhage into the leiomyoma (42). 
The tumor becomes mottled, beefy-red and soft, and microscopically a 
patchy necrosis associated with hemorrhagic muscle fibers is seen (42, 
45). Calcification tends to occur in postmenopausal women, with diffuse 
or focal changes within the leiomyoma (42). In extreme cases, the entire 
tumor may be converted into a calcified mass (43). Finally sarcomatous 
transformation is said to occur in leiomyomas, but this is very rare, less 
than 0.5-1% (42, 29). This is not considered to be the natural progression 
of leiomyomas, since the incidence of leiomyomas, which is relatively 
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high, does not correlate with the Incidence of uterine sarcomas which is 
low. 
C. Signs, Symptoms & Complications 
Uterine leiomyomas may produce several different signs and 
symptoms, or may remain totally asymptomatic. Between 20-50% of all 
leiomyomas are symptomatic (9, 29). Abnormal uterine bleeding is the 
most prevalent symptom, occurring in about 30% of patients (9, 29). it is 
usually manifested as menorrhagia, with heavy extended periods of 
menstrual bleeding associated with perimenstrual spotting. Metrorrhagia 
also frequently occurs in these patients. This abnormal uterine bleeding 
has been attributed to the presence of submucosal leiomyomas causing 
thinning and ulceration of the overlying endometrial mucosa (9, 29, 42). In 
a study by Fraser et al., submucosal and intrauterine pedunculated 
leiomyomas were found most frequently in patients with excessive 
bleeding (18). However, the incidence of submucosal leiomyomas is not 
high enough to account for the frequency of the abnormal uterine bleeding. 
Farber-Brown et al. have demonstrated compression of the venous plexi in 
the endometrium and myometrium by all three types of leiomyomas. This 
causes engorgement and dilation of the vessels, and predisposes the 
patient to excessive bleeding during menstruation (15, 16). It is also 
believed that the increased endometrial surface area due to protruding 
submucosal leiomyomas, and an impairment of uterine contractility by 
intramural leiomyomas may contribute to the menorrhagia (42). Patients 
may present with an iron deficiency anemia refractory to iron replacement 

therapy, or in a hypovolemic state due to excessive and rapid blood loss. 
These conditions can require surgical intervention. 
Pressure and pain were the presenting symptoms in 34% of patients 
with uterine leiomyomas in a review by Buttram et al. (9). Large tumors 
may impinge on the urinary bladder, causing urinary retention, 
incontinence, or frequency; compression of the ureters can cause 
hydroureters or hydronephrosis, compression of the pelvic vessels may 
cause lower extremity edema or varicosities. Pressure on the rectum or 
intestines may cause constipation and intestinal obstruction (29, 42). 
Patients may also complain of a general heaviness in the pelvic region. 
Pain often occurs with infection or carneous degeneration of a leiomyoma. 
Tumors may impinge on adjacent abdominal and pelvic viscera and nerves, 
causing pain that can radiate into the lower extremities (29). 
Pedunculated leiomyomas can undergo torsion, infarcting and producing 
acute pain (29, 42). Patients may also experience increased dysmenorrhea, 
which may be due to cramping caused by submucosal and intramural 
leiomyomas (42). Dyspareunia can also be associated with cervical 
leiomyomas (29). 
25-35% of patients with uterine leiomyomas are estimated to have 
infertility problems (43). Infertility is defined as the inability to conceive 
after one year of unprotected intercourse (54). Only about 2-10% of all 
cases of infertility can be solely attributed to these tumors (9, 29). There 
are usually other associated factors, such as pelvic inflammatory disease, 
endometriosis, anovulatory cycles, abnormal tubal and uterine motility, 
and various male partner factors (29) Uterine leiomyomas can cause 
infertility in several ways. Cervical and cornual tumors can impinge on the 
uterine and tubal lumens, obstructing the passage of sperm (9). 
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Submucosal and intramural leiomyomas may cause distortion of the 
uterine cavity, which may interfere with sperm passage or implantation of 
the fertilized ovum. Submucosal leiomyomas can also cause atrophy and 
ulceration of the overlying endometrium, producing an inappropriate milieu 
for the implantation and development of the embryo (9). This can also 
predispose the patient to spontaneous abortions. The occurrence of 
spontaneous abortions in pregnant women with uterine leiomyomas was 
found to be as high as 41% by Buttram et al., compared with an incidence 
rate of 10% in the general population. The rate of spontaneous abortions in 
women after myomectomies decreased to 19% (9), which is much closer to 
that of the general population. Multiple submucosal and intramural 
leiomyomas can distort, the uterine cavity, and decrease the uterine 
volume available for normal development of the fetus, increasing the 
chances of a spontaneous abortion. 
Once a patient with uterine leiomyomas becomes pregnant, she may 
face further problems associated with the tumors. Leiomyomas are 
associated with 0.3-7.2% of all pregnancies (42). The leiomyomas are 
usually present, and may be asymptomatic before pregnancy, but they tend 
to increase in size due to edema, hemorrhage into the tumor (29), and 
response to the increased estrogen levels. About 50% of leiomyomas that 
are present prior to pregnancy increase in size during the gestational 
period. The timing of the growth of the tumors varies depending on the 
original tumor size. Smaller leiomyomas tend to grow in the first and 
second trimesters, and regress thereafter. Larger tumors grow only during 
the first trimester, and regress in the second and third trimesters (32). 
The growth of the leiomyomas outstrips the blood supply to the tumors 
resulting in infarction, carneous degeneration and pain. Leiomyomas can 
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further complicate pregnancy by causing premature delivery, fetal 
representation, and dystocia due to cervical tumors causing obstruction. 
This could necessitate a cesarean section for safe delivery of the baby 
(29). Postpartum hemorrhage is also more frequent in a myomatous uterus 
(42), because of the inability of the uterus to contract and involute 
completely, producing inadequate hemostasis. Despite all these possible 
complications, several patients with large leiomyomas remain fertile, 
become pregnant, and carry their fetus to term (9, 42). 
D. Diagnosis 
In asymptomatic patients, a leiomyoma might be detected as an 
incidental finding during a gynecological exam, ultrasound, magnetic 
resonance imaging (MRI) study, or on an abdominal x-ray, if calcification 
has occurred. Some observant patients may notice an increase in abdominal 
girth. Some previously asymptomatic leiomyomas may enlarge during 
pregnancy, or with the use of exogenous estrogens, producing symptoms 
leading to their detection. In patients with symptoms such as abnormal 
uterine bleeding and pelvic pain or pressure (29), the clinical suspicion of 
leiomyomas would be very high. This can be initially evaluated with a 
pelvic exam, during which a uterine mass or nodularity may be palpated. 
Diagnostic imaging procedures are used for additional non-invasive 
work up. Ultrasonography (US) is usually the first imaging modality used in 
the evaluation of uterine leiomyomas. Computed tomography (CT), 
hysterosalpingography (HSG), and MRI are also used to evaluate 
leiomyomatous uteri. US is inexpensive, fast, and readily available (1) of 
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the imaging modalities. The ultrasonographic criteria used to diagnose 
leiomyomas include altered echo texture with inhomogeneity within the 
uterus, and an enlarged uterus with an irregular contour (22, 38). US can be 
used to distinguish between cystic and solid structures, and can, 
sometimes, give a reasonable estimation of the location of a leiomyoma 
(1). However, the quality of the US scan is highly dependent on the 
operator's expertise and the patient's habitus (26). Patients should have a 
full bladder to facilitate scanning (1), and excessive bowel gas (52) can 
block effective scanning. An enlarged uterus can also obscure adnexal 
pathology (1, 38). Leiomyomas are frequently misdiagnosed with US. 
Retroflexed uteri and uteri with developmental anomalies can cause 
contour irregularities that can mask leiomyomas (22, 24). Degenerating 
leiomyomas have been mistaken for fetal tissue (5). In one study, cystic 
degeneration of leiomyomas were misdiagnosed as an abnormal gestational 
sac - intrauterine location, and as an ectopic pregnancy - extrauterine 
location (3). US is also relatively inaccurate in distinguishing between 
subserosal pedunculated leiomyomas and extrauterine adnexal masses (22, 
38) or posterior subserosal tumors and masses in the cul-de-sac (5). With 
the advent of transvaginai ultrasonography (TVUS), imaging resolution and 
detail has been greatly improved, and the limitations of the patient's 
habitus and bladder volume have been eliminated. However, the field of 
view is very limited, so uterine enlargement and volume cannot be 
adequately assessed (41, 52). It also has a limited utility in children and 
postmenopausal women due to the smaller vaginal size in these patients 
(52). Although transabdominal US has inferior resolution when compared 
with TVUS, it is usually considered adequate for diagnosis and follow up 
of patients for whom no surgical intervention is planned. 
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CT scanning has very limited utility in the evaluation of uterine 
leiomyomas. It provides relatively poor tissue contrast, so uterine 
anatomy can not be clearly defined, and leiomyomas usually can not be 
accurately localized (33, 52). In addition to these disadvantages, ionizing 
radiation and intravenous contrast are used (33, 52). MR I is currently the 
optimal diagnostic modality for obtaining definitive information about 
uterine leiomyomas, especially when US is indeterminate, or if surgery is 
planned (13, 52, 61). MR! uses no ionizing radiation, and it is not as 
operator dependent as US. It is noninvasive, and is only limited by patient 
habitus when the patient is morbidly obese and cannot fit into the MR! 
scanner. It provides excellent tissue contrast and uterine anatomic detail 
(25, 36), and can be used to gain valuable information on the number, 
location, classification, vascularity and degeneration of leiomyomas (33). 
Three dimensional measurements can be obtained with ease, for use in 
calculating uterine and tumor volumes (6, 35). Excellent resolution is 
obtained with MR!, and tumors as small as 0.8 cm in diameter can be 
confidently identified, compared with minimum tumor diameters of 1.1 cm 
on US (61). MR! also has a wider field of view than US facilitating the 
evaluation of massively enlarged uteri. Zawin et al. found that enlarged 
uteri with volumes of 1429 cc could be measured with MR!, while the 
maximum volume US could accurately measure was 140 cc (6!). Dudiak et 
al. determined that MRI was better at detecting small tumors than US and 
HSG (13). In one group of patients, MR! had a sensitivity of 91 %, compared 
with 18% for HSG, in detecting abnormal uterine segments, in the same 
study, when compared to US, MRI sensitivity was 85%, while US 
sensitivity was 69% (13). MRI is also effective in distinguishing 
leiomyomas from other solid tumors when US is indeterminate (52, 59). 

MR!, however, does have some disadvantages, it is an expensive procedure, 
it is also susceptible to image degradation due to patient motion (6, 3). CT 
and US are less susceptible to this type of image degradation. 
Claustrophobic patients cannot undergo MRI scanning (52). Cardiac 
pacemakers, intracranial vascular clips (52), and any metallic 
ferromagnetic implants that could harm patients, by moving or 
malfunctioning under the magnetic force of the scanner, are major 
contraindications to MRi scanning. Despite these drawbacks, MRi is still 
the modality of choice for evaluating leiomyomas during hormonal theraoy 
(61), infertility work ups (37), and prior to surgery (13). US can De used to 
screen and follow up patients when no definitive treatment is planned 
(mob, 52). 
E. Treatment 
Treatment of uterine leiomyomas depends on the patient's menstrual 
status, the tumor size, the patient's wishes regarding fertility, and 
whether or not the patient is symptomatic (9). Until recently, the only 
options available were observation, with follow up, and surgery - either a 
hysterectomy or a myomectomy. The current use of gonadotropin-releasing 
hormone (GnRH) agonists provides a temporizing method for women who 
wish to postpone, or avoid surgery. Patients who are asymptomatic, or 
have only minor tolerable symptoms, with uterine size less than 10-12 
weeks gestation can be followed every 3-6 months with pelvic exams and 
US. This is usually adequate to monitor for rapid growth and complications 
(9, 42). These patients rarely have infertility problems due to the 

leiomyomas (9). Surgery is usually recommended for symptomatic 
patients, for patients with uteri larger than 10-12 weeks (9), and for 
patients whose adnexae can not be thoroughly evaluated because of the 
enlarged uterus. Surgery is required for patients with rapid, unaccountable 
growth of their leiomyomas, especially in postmenopausal women (9), in 
whom the risk of malignancy is higher. A dilatation and curettage should 
be followed by a hysterectomy in patients with abnormal uterine bleeding 
(9, 42) and anemia which is refractory to iron replacement and hormonal 
therapy. The definitive treatment for uterine leiomyomas is a 
hysterectomy (19). Many patients are resistant to having hysterectomies 
for various reasons, including the desire to preserve fertility (9), 
menstrual function (42), and other personal and psychological reasons. 
Myomectomies are also performed, but have the disadvantage of a 15-30% 
leiomyoma recurrence rate (9, 19). Both procedures also have the 
possibility of major blood loss (9, 42), which could make blood 
transfusions necessary. This increases the patient's risk of infection with 
the hepatitis or human immunodeficiency viruses. Postoperative adhesions 
can cause further complications of bowel obstruction and pain. 
GnRH agonists, such as leuprolide acetate have been shown to 
decrease uterine and leiomyoma size, usually within 3-6 months of 
treatment (11, 19, 51, 62). Symptoms associated with the leiomyomas, 
such as pelvic pressure, pain, and menorrhagia were relieved (11, 19, 51), 
and the vascularity of the tumors decreased (62). Friedman et al. found 
that patients with large uteri who received preoperative therapy with 
leuprolide acetate had decreased intraoperative blood loss when compared 
to those who received placebo (20). The main disadvantage of treatment 
with leuprolide acetate is that the uterus returns to the pretreatment size 

within about 3-6 months after treatment is stopped (19, 51), although the 
patients may remain symptom-free for several months longer (51). This 
rapid regrowth may be due to an increased number of estrogen receptors 
induced in the leiomyomatous tissues due to the hypoestrogenic action of 
leuprolide acetate (48). It also has many side effects, including hot 
flashes, mood changes, vaginal dryness and spotting, which are due to the 
decreased estrogen levels (20, 51). These effects are uncomfortable, may 
be tolerated (20, 51), but can be severe enough to cause premature 
cessation of therapy (21). Since the decrease in uterine size is net 
permanent, and growth recurs once the leuprolide acetate has been 
withdrawn, the drug is currently used as an adjunct to surgery. It 
decreases the leiomyoma size and vascularity, facilitating the surgical 
removal and minimizing blood loss (11, 19, 20). The induced amenorrhea 
reverses the anemia in patients with menorrhagia prior to treatment, also 
decreasing the need for intraoperative blood transfusions (11, 19). it can 
be used as a temporizing method for perimenopausai women, since 
leiomyomas tend to regress after menopause (19, 51). It can also be used 
in patients who are poor surgical risks (19), and in women who wish to 
shrink their leiomyomas, and undergo a trial of conception before any 
surgical intervention. 
It is unfortunate that the only known cure for uterine leiomyomas is 
a hysterectomy (19), however, each patient's treatment can be modified, 
depending on their presenting symptoms, age, and personal concerns to 
enable them to maintain a relatively normal lifestyle. 
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1 i. MAGNETIC RESONANCE IMAGING 
A. History 
The phenomenon of nuclear magnetic resonance (NMR) was first 
demonstrated by Bloch et al. (4), and Purcell et al. (47) working separately. 
They called it "nuclear induction" (4, 47). Further studies continued, with 
Odeblad and Lindstrom publishing a report on the first use of NMR on living 
animal tissues in 1955 (44). In 1973, Lauterbur published the first account 
of an image obtained with NMR (30). He produced an image of two 
containers of water (30). In 1976, the first image of human tissue, a 
finger, was produced by Mansfield and Maudsley (35). The field of NMR 
imaging (NMRI), frequently referred to as MRI, continued to develop 
rapidly, with increased utilization in humans. Extremely sophisticated and 
powerful scanners have been built, with advanced and innovative imaging 
techniques constantly being developed. 
B. Basic Principles 
The phenomenon of MRI is dependent on the magnetic qualities of 
atomic nuclei (14). When nuclei have unpaired protons or neutrons, they 
possess an intrinsic spin, and a magnetic moment (14, 53). In the absence 
of an external magnetic field, the magnetic moments of the nuclei are 
randomly oriented. However, when an external magnetic field is applied, 
the nuclei become aligned with the direction of the field, because of their 
magnetic moments (14, 46, 53). At equilibrium, this forms a net magnetic 
moment of all the nuclei (14, 46). The nuclei then rotate at a 
"precessional" or "resonant" frequency about the axis of the external field, 
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the "z-axis" (14, 46), This frequency is determined by the type of nuclei, 
and the strength of the magnetic field applied (14, 46, 53). These are 
related by the Larmor equation: 
V = y/2it*B0 , 
where v is the precessional frequency; X/2lt is the gyrornagnetic ratio, 
which is a constant that differs for each nucleus; and B0 is the magnetic 
field strength. 
Hydrogen is the most frequently used atom in MR imaging today (14, 
53). It is a stable atom with a single proton, and is ubiquitous as a 
component of water in the human body, except in compact bone where it is 
present in decreased concentrations (34, 53). For these reasons, the 
remaining discussion will focus on the use of the hydrogen nucleus 
(proton) in medical imaging. The gyrornagnetic ratio for hydrogen is 42.577 
megahertz ( MHz) at 1 Tesla (T) of field strength (46). The magnetic field 
strength of most scanners used for medical imaging ranges from 0.02-2.0 
T (46) These produce precessional frequencies in hydrogen of 0.2-84 MHz. 
When a static magnetic field is generated in the scanner, the hydrogen 
nuclei become oriented both parallel and antiparallel (53) to the z-axis 
and this produces a large z-component of the net magnetization vector, FI 
(14). The x and y components are zero, because although all the protons 
rotate at the same frequency, they are out of phase and therefore cancel 
each other out. When radiofrequency (RF) waves at the precessional 
frequency are directed at the nuclei in the x,y plane, the protons absorb 
energy, and are rotated from the z-axis (14, 46) This process is called 
excitation. These RF waves form excitation pulses which are characterized 
by the amount of rotation from the z-axis they produce - a 90° pulse 
rotates FI from the z-axis onto the x,y plane. This makes the FTZ component 
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zero, while the MXy component increases (14). The resumption of the 
equilibrium state from the excited state is called relaxation (14). it 
consists of two components: the reconstitution of the Mz component, also 
known as the spin-lattice relaxation, with a time constant Tl; and the 
loss of the Mxy component, also called the spin-spin relaxation, with a 
time constant T2 (14). During relaxation the protons emit the RF energy 
they previously absorbed, and this is received as the MR signal (53). This 
emission is the Rxy component of M (14). Three magnetic field gradients, 
oriented perpendicular to each other, are superimposed on the static 
magnetic field to provide spatial localization of the MR signal (33, 46, 53). 
The magnitude of the MR signal is directly proportional to the proton 
density in the tissue being scanned (53). The MR signal measured is always 
less than the original amplitude absorbed, because of losses during T1 and 
T2 relaxation (53). T1 relaxation is dependent on the environment 
surrounding the nucleus. As the excited nuclei return to equlibrium, they 
dissipate some of the absorbed RF energy to the environment. T1 measures 
this factor, and is the time, in milliseconds, for the recovery of 63% of the 
FTZ component (53). It varies with the static magnetic field of the scanner 
(53). The T2 relaxation is due to variable inhomogeneity in the magnetic 
field caused by identical adjacent nuclei interacting. It is the time, in 
milliseconds, required for the Mxy component to be reduced by 37% of the 
excitation level (53). T2 is independent of the magnetic field strength, but 
is dependent on the chemical properties of the protons (53). The difference 
between the T1 and T2 values of various tissues is an essential factor in 
the production of image contrast (14). 
Pulse sequences^consist of specific patterns of excitations and 
listening times (14). Spin echo sequences are frequently used, and consist 
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of an initial 90° excitation pulse, followed by a pause, then a 180° 
excitation pulse is delivered. This serves to correct any inhomogeneity in 
the magnetic field. The 130° pulse is followed by another pause, and then 
there is a listening period (14, 33, 46). The sequence is repeated after the 
listening period. The echo time, TE, is the time (milliseconds) between the 
first pulse (90°) and the listening period. The repetition time, TR, is the 
duration (milliseconds) of the entire pulse sequence before it is repeated 
(14). Variations of the spin echo sequence, such as the inversion recovery, 
!R, pulse sequence are also utilized. The !R pulse sequence consists of an 
initial 180° pulse, followed by a pause, then a 90° pulse, then a pause, 
another 180° pulse and finally, the listening period (14). Varying the pulse 
sequences used will produce differences in the extent of the T1 or T2 
weighting of the images obtained. The Mxy component is dependent on TE 
and TR during excitation and relaxation (14). If the TE is prolonged, during 
the listening period, there will be less FlXy and more Mz component. 
Therefore, the T1 dependence is decreased, and T2 dependence is increased 
(14). Increasing the TR (> 1500 msec), and the TE (> 60 msec) produces a 
T2 weighted image. Shorter TR (< 300 msec) and TE values (< 40 msec) 
produce T1 weighted images (14). Proton density dependent images have a 
short TE, similar to T1 weighted images, but have a long TR, similar to the 
T2 weighted images. The TE and TR parameters chosen, therefore, 
influence the MR signal intensity, because they determine now much signal 
is received after excitation. The MR signal intensity is therefore 
dependent on Tl, T2, the proton density of the tissue, and the pulse 
sequence being utilized. 
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C. Image Production 
Two dimensional MR images are produced for most medical purposes. 
MR scanners use the two dimensional Fourier transformation method (33). 
This involves the use of three weak magnetic gradients superimposed on 
the static magnetic field. These are oriented in orthogonal directions. One 
gradient, turned on during the 90° excitation pulse, is called the slice 
select gradient (33). The RF pulse excites a certain predetermined volume 
of protons, and in this way, the thickness of the slice is determined (33). 
The second gradient is the phase encoding gradient. This enables the 
location of the protons to be spatially encoded, due to changes in their 
spin frequencies that occur under the effect of the gradient. These changes 
cause the protons to fall out of the excitation phase induced by the 90° 
pulse. The changed phase angles can be recorded and analyzed to determine 
the location of the protons (33). The third gradient is called the frequency 
encoding or readout gradient. This is activated during the echo reception 
(listening period), and also causes changes in the proton frequencies. The 
location of the protons along the gradient can then be determined by the 
gradient strength, and the difference between the resonant frequency of 
the static magnetic field and the new proton frequencies (33). Each slice 
of tissue produces MR signal which is displayed in a map with the use of 
pixels and voxels (14, 33). Each volume of tissue sampled forms a volume 
element, or voxel. The length of the voxel corresponds to the slice 
thickness. One surface of the voxel forms the picture element, or pixel 
(33), and the signal from the entire voxel determines the signal intensity 
of the image (14, 33). Each voxel corresponds to a specific pixel, several 
of which are combined to form a signal intensity map in black and white 
(14, 33), while the phase frequency information maps out spatial location 
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(33). Several projections ranging from 128 to 512 are obtained, repeated 
and averaged to decrease data variation,and improve image resolution (14, 
33). Spatial resolution depends on the number of pixels (the image matrix 
size). The pixel size is affected by the size of the field of view (FOV), such 
that the pixel size = FOV/rnatrix size (33). Since smaller pixel sizes 
increase the spatial resolution, resolution can be improved by increasing 
matrix size without changing the FOV (33). This will, however, increase 
scanning time. Another alternative is to decrease the fov while 
maintaining the matrix size. This has the disadvantage of introducing 
imaging artifacts and decreasing the signal to noise ratio, SNR (33). The 
SNR reflects the ratio of MR signal to background noise. This can be 
improved with signal averaging, and the use of body surface coils. This 
produces shortened scan times, and better spatial and contrast resolution 
(33). 
One major disadvantage of MR1 is the amount of scanning time 
reguired. Scan time is the product of TR, the number of repetitions or 
excitations performed, and the number of the views obtained (14, 33), and 
can range from a few minutes to a few hours. It can be shortened by- 
decreasing TR, or cutting down the number of views and excitations. 
However, each alternative has disadvantages such as decreased image SNR 
(33) Techniques such as zero filling, echo planar and hybrid imaging, are 
methods of decreasing the number of views in scanning. Driven equilibrium 
and magnetic field gradient echo techniques are methods of decreasing TR, 
but in addition to the decreased SNR, the images produced are also more T1 
weighted (33). Most modern MR scanners have body surface coils, and other 
adaptations that increase the SNR (33). This is making it possible for 
several of the techniques mentioned above to be used to cut scan times 

20 
without significant image degradation. 
Artifacts can be introduced into MR! in several ways. External 
objects emitting RF waves, ferromagnetic objects on, or in the patient 
and voluntary or involuntary (cardiovascular, respiratory) patient motion 
can all produce image artifacts (33, 53). These can be minimized by signal 
averaging and gating techniques (33). Chemical shift and flow void 
artifacts which are due to characteristics or rapid motion of the protons 
being scanned also occur (33). Chemical shift artifacts can be decreased 
by using special pulse sequences and steeper magnetic gradients (33). With 
an understanding of how MR images are generated, it should be possible to 
anticipate artifacts, and minimize them by adjusting imaging techniques. 
D. Instrumentation 
MRI scanners consist of a large main magnet, which may be either a 
permanent magnet, an air core or iron core resistive magnet, or a 
superconductive magnet (33). This produces the static magnetic field 
which surrounds the patient. The three orthogonally oriented weaker 
magnetic gradients are produced by three coaxial electromagnet coils (33, 
46) that superimpose their fields on the static magnetic field. The RF 
coils are planar or solenoidal coils which usually serve as both the 
transmitter and receiver of the RF waves (33, 46) . The RF pulses received 
are then transmitted through a spectrometer to a computer where the 
image is generated (46). 

E. Patient Safety Concerns 
There are three main components of medical MR I which are being 
investigated for possible adverse effects on humans with frequent and 
prolonged exposure. These are the static magnetic fields (SMF), the 
extremely low frequency magnetic fields (ELFMF), and the RF waves used 
in imaging (46). There have been reports of patients with dental fillings 
experiencing strange taste and pain sensations when exposed to SMF up to 
1,5-2 T (46). There are, however, no reports of other detrimental effects 
directly attributable to SMF exposure (7, 46). There is evidence that 
neuronal stimulation or ventricular fibrillation can occur in some patients 
exposed to the rapidly changing ELFMF generated by the gradient coils (46). 
The RF waves generate heat in the patients' tissues, but this is usually 
easily dissipated through the skin (46). Another problem associated with 
the RF waves is interference with cardiac pacemaker functioning (46). 
This problem can be avoided by careful patient screening and with new 
developments in the manufacture of the pacemakers. Apart from these 
cases, there is no evidence of increased morbidity or mortality with low 
level exposure to RF waves (46, 49). 
Other safety hazards in MR imaging include the previously discussed 
effects of the magnetic fields on ferromagnetic objects, such as 
aneurysmal clips and pacemakers which could rotate and harm the patient. 
It is also difficult to monitor critically ill patients in the MR1 areas, 
because of the limited space in the scanner, and the use of metal in most 
monitoring devices (46). 
Despite some valid safety concerns with MR1, most patients prefer 
this imaging modality to CT scanning, because of the lack of ionizing 
radiation and IV or oral contrast (46). 
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F. MR 1 of the Female Pelvis 
MR I is particularly well suited to the study of the female pelvis. 
Multiple planes can be imaged without difficulty, it is noninvasive, and 
does not involve the use of ionizing radiation. This eliminates concerns 
about radiation effects on the female reproductive organs. Imaging of the 
female pelvis is often done to distinguish between uterine and ovarian 
pathology, and to obtain specific information about the location and type 
of lesion in the uterus. By altering the TE and TR parameters, 71 or 72 
weighted images can be obtained, producing excellent depictions of 
anatomy and soft tissue differentiation. T1 weighted images are excellent 
for differentiating between fat and smooth muscle (33), while 72 
weighted images provide anatomic detail and contrast between soft 
tissues. Tissues with short T1 values include fat, iron containing tissues 
as occur in a subacute hemorrhage, and some proteinaceous fluids appear 
bright on T1 weighted images (53). Tissues with long T1 values, such as 
ligaments, tendons, cerebrospinal fluid, urine and cortical bone appear 
darker on 71 weighted images (53). Muscle, inflammatory and neoplastic 
tissue have an intermediate signal on 71 weighted Images. Cortical bone, 
ligaments and tendons also have short T2 values, and have a low signal 
intensity on T2 weighted images, while iron containing tissues, 
inflammation, fluids, and neoplastic tissues appear bright, due to their 
long T2 values (33, 53). Fat has an intermediate signal intensity on T2 
images (33). 
The uterus in MR images appears as an organ with three intrinsic 
layers - the endometrium, myometrium, and the junctional zone, which Is a 
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low intensity layer only visualized with MR! (fig. I). The T1 values of 
endometrium and myometrium are similar, so there is not much tissue 
contrast on II weighted images (36). However, endometrium has a longer 
T2 than myometrium, so it emits a brighter signal than the myometrium on 
T2 weighted images. It is referred to as the endometrial stripe. MR! has 
been used to study the uterus during the menstrual cycle, and the 
endometrial stripe was observed to increase in thickness during the 
follicular and secretory phases, corresponding appropriately with the 
proliferative stage (28, 40). The changes in the endometrium under the 
Influence of oral contraceptives (12) and GnRH analogs (40) have also been 
studied with MR I. 
The myometrium is a region of intermediate intensity on T2 
weighted images. There is a thin layer of low Intensity between the 
endometrium and the myometrium called the junctional zone. Earlier 
studies defined this region as either the stratum basale, vasculature (12, 
25), or an area of flow void (31). However, a recent study by McCarthy et 
al. has demonstrated that the junctional zone is probably a tissue layer, 
within the myometrium, with a decreased water content, and low T2 
values (39) (hence the low signal intensity on T2 weighted scans). 
The cervix is usually visualized as a two layer region, with a 
intermediate Intensity signal obtained from the external fibrous stroma, 
and a bright central signal from the cervical mucus. There are venous plexi 
around the cervix and upper vagina which emit a bright signal (37). The 
vagina is also easily seen on T2 weighted Images as a central bright 
signal, due to mucus, surrounded by an intermediate signal from the 
fibromuscular walls. It is clearly distinct from the urethra (38). The 
ovaries are easily identifiable on T2 weighted images, because of the 

bright signal produced by the follicles (37). 
Because of the excellent resolution and soft tissue contrast 
obtained with MR I, it is possible to identify and accurately localize 
pathologic lesions within the pelvis, and to differentiate between ovarian, 
cul-de-sac, and uterine masses. It is also the technique of choice in 
evaluating the uterus, enabling definitive diagnoses which are essential 
for the appropriate management of uterine leiornyomatous disease, 
differentiating it from adenomyosis (57). 
Although supported by little data, it has always been generally 
accepted that certain characteristics of a leiornyomatous uterus, such as 
tumor size, type, degeneration and location correlate with clinical 
symptoms such as pain, infertility, and spontaneous abortions. More 
recently, Hricak et al. performed a study of 23 patients, which linked 
disruption of the junctional zone, observed on MRI, with hypermenorrhea 
(27). Their study, however, did not examine other MR! features of uterine 
leiomyoma disease for correlation with clinical symptoms other than 
hypermenorrhea. The purpose of this study is to use the excellent 
diagnostic capabilities of MRI, combined with patients' clinical histories, 
to examine any possible correlation between leiomyoma characteristics 
and patient symptoms and signs, such as menorrhagia, metrorrhagia, 
abdominal/pelvic pain, back pain, dysmenorrhea, dyspareunia, infertility, 
and spontaneous abortion. 
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2. METHODS 
!. PATIENT SELECTION 
The study subjects were selected from a group of women who were 
evaluated for uterine fibroid disease at the Yale Obstetrics and Gynecology 
Infertility and Endocrine Clinic between October 1986 and December 1990. 
45 patients were selected based on the following criteria: 
Definite evidence of uterine leiomyomas on MR imaging - presence 
of discrete rounded hypointense masses within the uterus. 
A record of a clinical evaluation and an MRI study performed 
within 0-60 days of each other. 
The patients' age range was 25-54 years, with a mean age of 36.3 years. A 
total of 1 14 clinical visits associated with concurrent MRI studies were 
reviewed. 
II. CLINICAL DATA COLLECTION 
All the patients' charts were reviewed, and the following clinical 
data were recorded from the histories obtained at the clinical visit: 
The presence or absence of symptoms 
The presence or absence of pain 
The anatomic location of pain: abdominal/pelvic or back pain 
The presence or absence of pressure 
The presence or absence of 2° dysmenorrhea, or an increase in the 

severity of 1° dysmenorrhea 
The presence or absence of dyspareunia 
The presence or absence of menorrhagia 
The presence or absence of metrorrhagia 
History of infertility 
History of spontaneous abortion 
Uterine size in gestational weeks from a bimanual exam 
This data was then tabulated for subsequent analysis. 
11. IMAGING TECHNIQUES 
A total of 114 MRI studies performed between October 1986 and 
December 1990 were reviewed. MR imaging was performed with a 1.5 T 
Signa scanner (General Electric Medical Systems, Milwaukee). Spin echo 
axial and sagittal images were obtained with two excitations, 28 cm FGV, 
and a 128* 256 matrix. T1 weighted images were produced with a TR of 
400-800 msec, and a TE of 20-40 msec with 5-10 millimeter (mm) thick 
slices with 2.5-5.0 mm gaps. Intermediate and T2 weighted images were 
obtained with a TR of 1500-2200 msec and a TE of 20/80 msec, using 5 
mm thick slices, and 2.0-5.0 mm gaps. All the MRI studies obtained were 
reviewed by a blinded investigator, (E.B.) who had no knowledge of the 
patients' clinical data. 

IV. MAGNETIC RESONANCE IMAGING DATA COLLECTION 
The pelvic images were evaluated for total uterine volume, (TUV), 
the presence of uterine leiomyomas, and various characteristics to be 
described. All dimensions were measured manually with calipers. The 
following information was amassed: 
Three uterine dimensions, consisting of the anterior-posterior 
diameter (AP), which was measured on sagittal images as the widest AP 
thickness of the mid-corpus, the cranio-caudad height (CC), which was 
obtained from sagittal views as the greatest length from (and Including) 
the cervix to the top of the fundus, and the transaxial width (TR) which 
was obtained from transaxial views as the widest measurement of the 
uterine corpus. Subserosal leiomyomas projecting from, and distorting the 
uterine contour were included in the maximum diameters. (Fig 2). 
The dimensions, (AP,CC,TR) of the discrete countable leiomyomas 
were obtained in the same planes as the uterine dimensions.if a leiomyoma 
was spherical, and was measured in one image plane, but was absent in the 
other planes due to scanning gaps, the single dimension obtained was used 
in the volume calculations. 
The locations of the leiomyomas within the uterus were recorded as 
follows: body, fundus, cervix, broad ligament, and cornual. The category of 
'‘multiple" was used when the leiomyomas were too many, and too small to 
identify and measure with certainty. 
The junctional zone appearance was categorized as present, intact 
or disrupted. 
The type of leiomyoma was noted as follows: submucosal 
leiomyomas had the tumor epicenter in the submucosa, and were noted to 

disrupt the contiguous junctional zone (figs. 3 & 4); intramural 
leiomyomas had the epicenter in the myometrium, and did not disrupt the 
junctional zone (figs. 5 & 6); subserosal leiomyomas had the epicenter in 
the myometrium directly beneath the subserosa, with the bulk of the 
tumor bulging into the subserosal layer (figs. 2 & 6). 
Finally, the types of degenerative changes in the leiomyomas were 
noted based on the tumors' internal signal. The degeneration was 
categorized as "non-specific", when the tumor had some signal increase 
and inhomogeneity, which could not be definitely classified as fatty or 
carneous (figs. 2 - 6). Although this probably represented hyaline 
degenerative change, we did not classify it as such, since there are only a 
few conclusive reports of a characteristic MR appearance for this type of 
degeneration (27, 31), and we did not have histopathologic correlation 
available. Carneous degeneration was diagnosed when there was a bright 
signal within a tumor on 12 images, and an intermediate to bright signal 
on Tl images, signifying a probable subacute hemorrhage (10, 23, 33, 55). 
Fatty degeneration was identified when the tumor's internal signal was of 
the same intensity as the subcutaneous fatty tissue. The category of "no 
degeneration" was used when the leiomyoma had a homogeneous signal. 
V. PAT! ENT/MR I SCAN PROFILE 
The number of visit days per patient ranged from 1 -6 days. The mean 
time between the 1 14MR1 studies and clinical visits was 14 days (range 
of 0-51 days). Twenty-nine scans were performed on the same day as the 
clinical visit, 30 scans were performed within 1-10 days of the clinical 
visit, 29 scans were performed within 1 1-20 days of the clinical visit, 10 
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scans were performed within 21-30 days of the clinical visit, 10 scans 
were performed within 31-40 days of the clinical visit, 5 scans were 
performed within 41-50 days of the clinical visit, and 1 scan was 
performed within 51 days of the clinical visit. Since the patients' 
symptoms varied during their clinical evaluations, the MR I results were 
re-evaluated for each consecutive scan, yielding a total of 317 MR!- 
clinical data correlations. Twenty-nine out of the 45 patients in this study 
were on leuproiide acetate for a portion of their clinical course; 5 of these 
29 patients were initially on placebo, and then elected to undergo 
treatment with the drug after the study ended. Two patients received 
placebo, but did not subsequently receive leuproiide acetate. (All the 31 
patients described above were subjects in previous studies unrelated to 
this current study). Fourteen patients did not receive any drug treatment. 
A total of 47 scans were performed while patients were on leuproiide 
acetate, and the remaining 57 scans comprised the no drug group. The data 
obtained when patients were on leuproiide acetate was examined 
separately from the placebo and the no drug group. The data obtained from 
the placebo group was compared to the no drug group to detect any 
differences in the clinical data due to a "placebo effect" on the subjective 
information given by the patients. No significant differences in the results 
were noted (p > 0.05), so the placebo group results were combined with the 
no drug group results for further statistical analysis. 
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Vi. PRELIMINARY DATA ANALYSIS 
The uterine and leiomyoma volumes were computed using the 
equation: Volume (cc) = ‘Vjw * AP/2 x CC/2*TR/2 . The non-leiomyoma 
uterine volume was obtained as the difference between the uterine volume 
and the total leiomyoma volume in each uterus. Nine uterine size 
estimations by bimanual exam were expressed as the number of 
centimeters above the pubic symphysis. These measurements were 
converted to gestational weeks size, by referring to data compiled by 
Baeyertz that related symphysio-fundal height in 127 women to the 
gestational age in weeks of their fetuses (2). The uterine size in 
gestational weeks was converted to volume measurements with the use of 
an equation derived by Flickinger et al (17): 
Volume = 0.1 13w3 + 2.084w2 + 12.396w + 23.397 
The uterine volumes obtained by MR! and bimanual exams were then 
examined for any correlation. The MR! uterine volumes were plotted on a 
graph against the bimanual uterine volumes, and the correlation 
coefficient was calculated. The clinical findings of menorrhagia, 
metrorrhagia, abdominal/pelvic pain, back pain, dysmenorrhea, 
dyspareunia, infertility, and spontaneous abortion were correlated with 
concurrent MR! findings of leiomyoma locations, types, degeneration, and 
volumes, uterine volumes and junctional zone disruption. The significance 
of the information obtained from these correlations was tested with chi- 
square analysis. 
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3. RESULTS 
Forty-three of the 45 patients had one or more symptoms. The most 
frequently reported symptom was menorrhagia, followed by 
abdominal/pelvic pain, metrorrhagia, dysmenorrhea, dyspareunia, 
infertility, spontaneous abortion, and back pain (Table 1). The number of 
leiomyomas per patient ranged from 1-10 discrete countable tumors, with 
a total of 136 different leiomyomas for 43 of the patients. The two other 
patients had tumors that were multiple, tiny (< 0.5 centimeters diameter) 
and could not be counted. 
TABLE 1. Frequency of patients' symptoms and signs 
Symptoms/Signs 
Menorrhagia 
A/P Pain 
Metrorrhagia 
Dysmenorrhea 
Dyspareunia 
Infertility 
Spontaneous Abortion 
Back Pain 
Number of Patients (%) 
32 (71%) 
23(51%) 
22(49%) 
21(47%) 
10(22%) 
10(22%) 
4 (9%) 
2 (4%) 
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I. JUNCTIONAL ZONE (JZ) DISRUPTION 
The junctional zone on 1 1 1 scans clearly defined. The junctional 
zone was not seen clearly enough on 3 scans to be categorized as intact or 
disrupted. 
Menorrhagia: 
Leuprolide acetate 
1/33 (3 %) of all scans with JZ disruption had menorrhagia. 
1/10 (10%) of all scans with intact JZ had menorrhagia 
p = 0.8822 
No Drug Treatment 
32/42 (76%) of all scans with JZ disruption had menorrhagia. 
11/21 (52%) of all scans with intact JZ had menorrhagia. 
p = 0.10J8 
Leuprolide acetate compared to no drug treatment 
1/33 (3 %) of all scans with JZ disruption on leuprolide acetate had 
menorrhagia compared to 32/42 (75%) on no drug treatment. 
p = 0.000/ 
1/10 (10%) of all scans with intact JZ on leuprolide acetate had 
menorrhagia compared to 11/21 (52%) on no drug treatment. 
p = 0.06/5 
Metrorrhagia: 
Leuprolide acetate 
13/33 (34%) of all scans with JZ disruption had metrorrhagia. 
1/10(10%) of all scans with intact JZ had metrorrhagia. 
p = 0.268 
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Mo Drug Treatment 
15/42 (36%) of all scans with JZ disruption had metrorrhagia. 
3/21 (15%) of all scans with intact JZ had metrorrhagia. 
p = 0.1J91 
Leuproiide acetate compared to no drug treatment 
13/38 (34 %) of all scans with JZ disruption on leuproiide acetate 
had metrorrhagia compared to 15/42 (36%) on no drug treatment. 
p = 0.9252 
1/10 (10%) of all scans with intact JZ on leuproiide acetate had 
metrorrhagia compared to 3/21 (15%) on no drug treatment. 
p = 0.8/0/ 
Spontaneous Abortion: 
4/32 (13%) of patients with JZ disruption had a history of 
spontaneous abortion compared to 0/12 (0%) of patients with intact JZ. 
p = 0.4866 
Infertility: 
11/29 (38%) of patients with disrupted JZ had a history of 
infertility compared to 1/10(10%) of patients with intact JZ. 
p = 0.2 J 02 
11. LEIOMYOMA LOCATION 
The dominant leiomyoma within each uterus from each MR! study 

34 
was evaluated for the location, which was then correlated with A/P and 
back pain, pressure and infertility. 
Pressure: 
Leuprolide Acetate 
3/33 (9%) of all scans with the dominant leiomyoma in the uterine 
body had pressure. 
0/2 (0%) of all scans with the dominant leiomyoma in the uterine 
cervix had pressure. 
2/8 (25%) of all scans with the dominant leiomyoma in the uterine 
fundus had pressure. 
0 scans had the dominant leiomyoma in the broad ligament. 
0/3 (0%) of all scans with the dominant leiomyoma in multiple 
uterine sites had pressure. 
0 scans had no leiomyomas visualized. 
p = 0.4999 
No Drug Treatment 
12/34 (47%) of all scans with the dominant leiomyoma in the 
uterine body had pressure. 
1/1 (100%) of all scans with the dominant leiomyoma in the uterine 
cervix had pressure. 
3/13 (23%) of all scans with the dominant leiomyoma in the uterine 
fundus had pressure. 
1/1 (100%) of all scans with the dominant leiomyoma in the broad 
ligament had pressure. 
1/7 (14%) of all scans with leiomyomas in multiple uterine sites 
had pressure. 

0/2 (0%) of all scans with no leiomyomas visualized had pressure. 
p = 0.245J 
Leuprolide acetate compared with no drug treatment 
3/33 (9 %) of scans with the dominant leiomyoma in the uterine 
body on leuprolide acetate had pressure compared with 12/34 (47%) of 
scans on no drug treatment. 
p = 0.0J56 
0/2 (0 %) of scans with the dominant leiomyoma in the uterine 
cervix on leuprolide acetate had pressure compared with 1/1 (100%) of 
scans on no drug treatment. 
p = 0.655 
2/3 (25%) of scans with the dominant leiomyoma in the uterine 
fundus on leuprolide acetate had pressure compared with 3/13 (23%) of 
scans on no drug treatment. 
p = 0.6694 
0 scans had the dominant leiomyoma in the broad ligament on 
leuprolide acetate. 
0/3 (0%) of scans with the dominant leiomyoma in multiple uterine 
sites on leuprolide acetate had pressure compared with 1/7 (14%) of scans 
on no drug treatment. 
0 scans had no leiomyomas visualized on leuprolide acetate. 
p = 0.6455 
Abdorninal/Pelvic Pain: 
Leuprolide Acetate 
7/33 (21%) of scans with the dominant leiomyoma in the uterine 
body had abdominal/pelvic pain. 
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0/2 (0%) of scans with the dominant leiomyoma in the uterine 
cervix had abdominal/pelvic pain. 
2/8 (25%) of scans with the dominant leiomyoma m the uterine 
fundus had abdominal/pelvic pain. 
0 scans had leiomyomas in the broad ligament. 
1/3 (33%) of scans with the dominant leiomyoma in multiple sites 
had abdominal/pelvic pain. 
0 scans had no leiomyomas visualized. 
p = O.SJS 
No Drug Treatment 
14/34 (47%) of scans with the dominant leiomyoma in the uterine 
body had abdominal/pelvic pain. 
0/1 (0%) of scans with the dominant leiomyoma in the uterine 
cervix had abdominal/pelvic pain. 
7/13 (54%) of scans with the dominant leiomyoma in the uterine 
fundus had abdominal/pelvic pain. 
0/1 (0%) of scans with the dominant leiomyoma in the broad 
ligament had abdominal/pelvic pain. 
4/7 (57%) of scans with the dominant leiomyoma in multiple sites 
had abdominal/pelvic pain. 
0/2 (0%) of scans with no leiomyomas visualized had 
abdominal/pelvic pain. 
p = 0.2J9 
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Leuprolide acetate compared to no drug treatment 
7/33 (21%) of scans with the dominant leiomyoma in the uterine 
body on leuprol ide acetate had abdominal/pelvic pain compared with 14/34 
(47%) of scans on no drug treatment. 
p = 0.4JS 
0/2 (0 %) of scans with the dominant leiomyoma in the uterine 
cervix on leuprolide acetate had abdominal/pelvic pain compared with 0/1 
(0%) of scans on no drug treatment. 
p = not calculable 
2/8 (25%) of scans with the dominant leiomyoma in the uterine 
fundus on leuprolide acetate had abdominal/pelvic pain compared with 
7/13 (54%) of scans on no drug treatment. 
p = 0.J991 
0 scans had the dominant leiomyoma in the broad ligament on 
leuprolide acetate. 
1/3 (33%) of scans with the dominant leiomyoma in multiple uterine 
sites on leuprolide acetate had abdominal/pelvic pain compared with 4/7 
(57%) of scans on no drug treatment. 
0 scans had no leiomyomas visualized on leuprolide acetate. 
p = 0.6455 
Sack Pain 
Leuprolide Acetate 
2/2 (100%) of scans with back pain had the dominant leiomyoma in 
the uterine body. 
No Drug Treatment 
0 scans were associated with back pain. 
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Infertility 
6/32 (19%) of all patients with a dominant leiomyoma in the uterine 
body had a prior history of infertility. 
1/2 (50%) of all patients with a dominant leiomyoma in the uterine 
cervix had a prior history of infertility. 
3/9 (33%) of all patients with a dominant leiomyoma in the uterine 
fundus had a prior history of infertility. 
0/1 (0%) of all patients with a dominant leiomyoma in the broad 
ligament had a prior history of infertility. 
0/1 (0%) of all patients with a dominant leiomyoma in multiple 
uterine sites had a prior history of infertility. 
0 patients with leiomyomas that were not visualized had a history 
of infertility. 
p = 0.6752 
III. LEIOMYOMA TYPE 
The different types of leiomyomas (submucosal, intramural, and 
subserosal) in each MRI study were evaluated, and correlated with 
menorrhagia, dysmenorrhea, infertility, and spontaneous abortion. 
Infertility: 
13/32 (41%) of patients with submucosal leiomyomas had a prior 
history of infertility. 

7/22 (32%) of patients with intramural leiomyomas had a prior 
history of infertility. 
2/11 (13%) of patients with subserosal leiomyomas had a prior- 
history of infertility. 
0/10 (0%) of patients with multiple leiomyomas had a prior history 
of infertility. 
3/9 (33%) of patients with no leiomyomas visualized had a prior 
history of infertility. 
p = 0.1441 
Spontaneous Abortion: 
4/32 (25%) of patients with submucosal leiomyomas had a prior 
history of spontaneous abortion. 
2/24 (3%) of patients with intramural leiomyomas had a prior 
history of spontaneous abortion. 
1/13 (7%) of patients with subserosal leiomyomas had a prior 
history of spontaneous abortion. 
0/10 (0%) of patients with multiple leiomyomas had a prior history 
of infertility. 
0/9 (0%) of patients with no leiomyomas visualized had a prior 
history of spontaneous abortion. 
p = 0.62! J 
Dysmenorrhea: 
Leuprolide Acetate 
1/46 (2%) of all scans with at least 1 submucosal leiomyoma had 
dysmenorrhea. 
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2/23 (12%) of all scans with at least 1 intramural leiomyoma had 
dysmenorrhea. 
1/15 (7%) of all scans with at least 1 subserosal leiomyoma had 
dysmenorrhea. 
0/3 (0%) of all scans with multiple leiomyomas had dysmenorrhea. 
0/5 (0%) of all scans with no leiomyomas visualized had 
dysmenorrhea. 
p = 0.7/26 
No Drug Treatment 
14/49 (29%) of all scans with at least 1 submucosal leiomyoma had 
dysmenorrhea. 
15/25 (60%) of all scans with at least 1 intramural leiomyoma had 
dysmenorrhea. 
5/19 (36%) of ail scans with at least 1 subserosal leiomyoma had 
dysmenorrhea. 
0/7 (0%) of all scans with multiple leiomyomas had dysmenorrhea. 
3/3 (100%) of ail scans with no leiomyomas visualized had 
dysmenorrhea. 
p = 0.00/6 
Leuorolide acetate compared to no drug treatment 
1/46 (2%) of all scans with at least 1 submucosal leiomyoma on 
leuprolide acetate had dysmenorrhea compared to 14/49 (29%) of scans 
with no drug treatment. 
p = 0.0012 
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2/23 (12%) of all scans with at least 1 intramural leiomyoma on 
leuprolide acetate had dysmenorrhea compared to 15/25 (60%) of scans 
with no drug treatment. 
p = 0.0006 
1/15 (7%) of all scans with at least 1 subserosal leiomyoma on 
leuprolide acetate had dysmenorrhea compared to 5/19 (36%) of scans 
with no drug treatment. 
p = 02987 
0 scans with multiple leiomyomas had dysmenorrhea. 
0/5 (0%) of all scans with no leiomyomas visualized on leuprolide 
acetate had dysmenorrhea compared to 3/3 (100%) scans on no drug 
treatment. 
p = 0.038! 
Menorrhagia: 
Leuprolide Acetate 
1/38 (3%) of all scans with at least 1 submucosal leiomyoma had 
menorrhagia. 
0/2 (0%) of all scans with at least 1 intramural leiomyoma had 
menorrhagia. 
0/4 (0%) of all scans with at least 1 subserosal leiomyoma had 
menorrhagia. 
0/2 (0%) of all scans with multiple leiomyomas had menorrhagia. 
1/2 (50%) of all scans with both intramural and subserosal 
leiomyomas had menorrhagia. 
p = 0.0255 
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No Drug Treatment 
32/42 (76%) of all scans with at least 1 submucosal leiomyoma had 
menorrhagia. 
5/7 (71%) of all scans with at least 1 intramural leiomyoma had 
menorrhagia. 
3/6 (50%) of all scans with at least 1 subserosai leiomyoma had 
menorrhagia. 
0/5 (0%) of all scans with multiple leiomyomas had menorrhagia. 
3/3 (100%) of all scans with both intramural and subserosai 
leiomyomas had menorrhagia. 
p = 0.006J 
Leuorolide acetate compared to no drug treatment 
1/38 (3%) of all scans with at least 1 submucosal leiomyoma on 
leuprolide acetate had menorrhagia compared to 32/42 (76%) of scans 
with no drug treatment. 
p = 00001 
0/2 (0%) of all scans with at least 1 intramural leiomyoma on 
leuprolide acetate had menorrhagia compared to 5/7 (71%) of scans with 
no drug treatment. 
p = 03241 
0/4 (0%) of all scans with at least 1 subserosai leiomyoma on 
leuprolide acetate had menorrhagia compared to 3/6 (50%) of scans with 
no drug treatment. 
p = 03241 
0/2 (0%) of all scans with multiple leiomyomas on leuprolide 
acetate had menorrhagia compared to 0/5 (0%) scans on no drug treatment. 
p = not calculable 
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1/2 (50%) of all scans with both intramural and subserosa! 
leiomyomas on leuprolide acetate had menorrhagia compared to 3/3 (100%) 
of scans with no drug treatment. 
p= 0.8195 
IV. LEIOMYOMA DEGENERATION 
A total of 296 leiomyomas were evaluated for any association 
between degenerative changes, tumor volume and pain. 
Leiomyoma Volume: 
Leuprolide Acetate 
1/85 (1%) of all the leiomyomas with volumes between 0-49.9 cc 
had carneous degeneration. 
3/17(18%) of all the leiomyomas with volumes between 50-99.9 cc 
had carneous degeneration. 
4/24(17%) of all the leiomyomas with volumes between 100-499.9 
cc had carneous degeneration. 
0/2 (0%) of all the leiomyomas with volumes between 500-999.9 cc 
had carneous degeneration. 
There were no leiomyomas with volumes between 1000-2200 cc. 
p = 0.0071 

No Drug Treatment 
5/108 (5%) of all the leiomyomas with volumes between 0-49.9 cc 
had carneous degeneration. 
3/16 (19%) of all the leiomyomas with volumes between 50-99.9 cc 
had carneous degeneration. 
4/20 (20%) of all the leiomyomas with volumes between 100-499.9 
cc had carneous degeneration. 
4/14 (20%) of all the leiomyomas with volumes between 500-999.9 
cc had carneous degeneration. 
0/1 (0%) of all the leiomyomas with volumes between 1000-2200 
had carneous degeneration. 
p = 00/43 
Leuprolide Acetate 
51/85 (60%) of all the leiomyomas with volumes between 0-49.9 cc 
had no degeneration. 
0/17 (0%) of all the leiomyomas with volumes between 50-99.9 cc 
had no degeneration. 
0/24(0%) of all the leiomyomas with volumes between 100-499.9 
cc had no degeneration. 
0/2 (0%) of all the leiomyomas with volumes between 500-999.9 cc 
had no degeneration. 
There were no leiomyomas with volumes between 1000-2200 cc. 
p = 0000/ 
No Drug Treatment 
55/108 (51%) of all the leiomyomas with volumes between 0-49.9 
cc had no degeneration. 
3/16 (19%) of all the leiomyomas with volumes between 50-99.9 cc 
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had no degeneration. 
1/20 (5%) of all the leiomyomas with volumes between 100-499.9 
cc had no degeneration. 
0/14 (0%) of all the leiomyomas with volumes between 500-999.9 
cc had no degeneration. 
0/1 (0%) of all the leiomyomas with volumes between 1000-2200 
had no degeneration. 
p = 0.0001 
Leuprolide Acetate 
33/85 (39%) of all the leiomyomas with volumes between 0-49.9 cc 
had non-specific degenerative changes. 
14/17 (82%) of all the leiomyomas with volumes between 50-99.9 
cc had non-specific degenerative changes. 
20/24 (83%) of all the leiomyomas with volumes between 100- 
499.9 cc had non-specific degenerative changes. 
2/2 (100%) of all the leiomyomas with volumes between 500-999.9 
cc had non-specific degenerative changes. 
There were no leiomyomas with volumes between 1000-2200 cc. 
p = 0.0001 
No Drug Treatment 
49/108 (45%) of all the leiomyomas with volumes between 0-49.9 
cc had non-specific degenerative changes. 
10/16 (63%) of all the leiomyomas with volumes between 50-99.9 
cc had non-specific degenerative changes. 
15/20 (75%) of all the leiomyomas with volumes between 100- 
499.9 cc had non-specific degenerative changes. 
10/14(71%) of all the leiomyomas with volumes between 500- 
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999.9 cc had non-specific degenerative changes. 
1/1 (100%) of all the leiomyomas with volumes between 1000- 
2200 cc had non-specific degenerative changes. 
p = 0.0442 
Leuproiide acetate compared to no drug treatment 
1/85 (1%) of leiomyomas with volumes between 0-49.9 cc on 
leuproiide acetate had cameous degeneration compared to 5/108 (5%) on 
no drug treatment. 
p = 0.2J98 
3/17 (18%) of leiomyomas with volumes between 50-99.9 cc on 
leuproiide acetate had cameous degeneration compared to 3/15 (19%) on 
no drug treatment. 
p = 0.7! 18 
4/24 (17%) of leiomyomas with volumes between 100-499.9 cc on 
leuproiide acetate had cameous degeneration compared to 4/20 (20%) on 
no drug treatment. 
p= 09/48 
0/2 (0%) of leiomyomas with volumes between 500-999.9 cc on 
leuproiide acetate had cameous degeneration compared to 4/14 (29%) on 
no drug treatment. 
p = 1.0000 
51/85 (60%) of leiomyomas with volumes between 0-49.9 cc on 
leuproiide acetate had no degeneration compared to 55/108 (51%) on no 
drug treatment. 
p = 0.2661 
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0/17 (0%) of leiomyomas with volumes between 50-99.9 cc on 
leuprolide acetate had no degeneration compared to 3/16 (19%) on no drug 
treatment. 
p = 0.205J 
0/24 (0%) of leiomyomas with volumes between 100-499 9 cc on 
leuprol ide acetate had no degeneration compared to 1/20 (5%) on no drug 
treatment. 
p = 0.9264 
0/2 (0%) of leiomyomas with volumes between 500-999.9 cc on 
leuprol ide acetate had no degeneration compared to 0/14 (0%) on no drug 
treatment. 
p = not calculable 
33/85 (39%) of leiomyomas with volumes between 0-49.9 cc on 
leuprol ide acetate had non-specific degenerative changes compared to 
49/108 (45%) on no drug treatment. 
p = 0.4452 
14/17 (82%) of leiomyomas with volumes between 50-99.9 cc on 
leuprol ide acetate had non-specific degenerative changes compared to 
10/16 (63%) on no drug treatment. 
p = 0.J741 
20/24(83%) of leiomyomas with volumes between 100-499.9 cc on 
leuprol ide acetate had non-specific degenerative changes compared to 
15/20 (75%) on no drug treatment. 
p = 0.7588 

A D 
“HO 
2/2 (! 00%) of leiomyomas with volumes between 500-999.9 cc on 
leuprolide acetate had non-specific degenerative changes compared to 
10/14(71%) on no drug treatment. 
p = 1.0000 
Abdominal/Pelvic Pain: 
Leuprolide Acetate 
1/8 (13%) of all the carneous leiomyomas were associated with 
abdominal/pelvic pain. 
13/51 (26%) of all the leiomyomas with no degeneration were 
associated with abdominal/pelvic pain. 
15/72 (21%) of all the leiomyomas with non-specific degenerative 
changes were associated with abdominal/pelvic pain. 
p= 06500 
No Drug Treatment 
9/16 (56%) of all the carneous leiomyomas were associated with 
abdominal/pelvic pain. 
13/59 (22%) of all the leiomyomas with no degeneration were 
associated with abdominal/pelvic pain. 
25/90 (28%) of all the leiomyomas with non-specific degenerative 
changes were associated with abdominal/pelvic pain. 
p - 00262 
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Leuprol 1 de acetate compared to no drug treatment 
1/8 (13%) of all the carneous leiomyomas on leuprolide acetate 
were associated with abdominal/pelvic pain compared to 9/16 (56%) on no 
drug treatment. 
p = 0.1073 
13/51 (26%) of all the leiomyomas with no degenerative changes on 
leuprol ide acetate were associated with abdominal/pelvic pain compared 
to 13/59 (22%) on no drug treatment. 
p = 0.8411 
15/72 (21%) of all the leiomyomas with non-specific degenerative 
changes on leuprol ide acetate were associated with abdominal/pelvic pain 
compared to 25/90 (28%) on no drug treatment. 
p = 0.4036 
Back Pain: 
Only 2 leiomyomas in the entire study were associated with back 
pain; both were on leuprol Ide acetate treatment, and had no degenerative 
changes (2/59). 
Dysmenorrhea: 
Leuprolide Acetate 
0/3 (0%) of ail the carneous leiomyomas were associated with 
dysmenorrhea. 
2/60 (3%) of all the leiomyomas with no degeneration were 
associated with dysmenorrhea. 
3/72 (4%) of all the leiomyomas with non-specific degenerative 
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changes were associated with dysmenorrhea. 
p - 0.8269 
No Drug Treatment 
9/!6 (56%) of all the carneous leiomyomas were associated with 
dysmenorrhea. 
25/71 (35%) of all the leiomyomas with no degeneration were 
associated with dysmenorrhea. 
30/90 (33%) of all the leiomyomas with non-specific degenerative 
changes were associated with dysmenorrhea. 
p = 0.075J 
Leuprolide acetate compared to no drug treatment 
0/8 (0%) of all the carneous leiomyomas on leuprolide acetate were 
associated with dysmenorrhea compared to 9/16 (56%) on no drug 
treatment. 
p = 0.025J 
2/60 (3%) of all the leiomyomas with no degenerative changes on 
leuprolide acetate were associated with dysmenorrhea compared to 25/71 
(35%) on no drug treatment. 
p = 0.001 
3/72 (4%) of all the leiomyomas with non-specific degenerative 
changes on leuprolide acetate were associated with dysmenorrhea 
compared to 30/90 (33%) on no drug treatment. 
p = 0.1JJJ 
Dvspareunia: 
Leuprolide Acetate 
0/8 (0%) of all the carneous leiomyomas were associated with 
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dyspareunia. 
6/60 (10%) of all the leiomyomas with no degeneration were 
associated with dyspareunia. 
2/72 (3%) of ail the leiomyomas with non-specific degenerative 
changes were associated with dyspareunia. 
p= 0.1586 
No Drug Treatment 
4/16 (25%) of all the carneous leiomyomas were associated with 
dyspareunia. 
12/71 (17%) of all the leiomyomas with no degeneration were 
associated with dyspareunia. 
9/90 (10%) of all the leiomyomas with non-specific degenerative 
changes were associated with dyspareunia. 
p - 0.1946 
Leuorolide acetate compared to no drug treatment 
0/8 (0%) of all the carneous leiomyomas on ieuprolide acetate were 
associated with dyspareunia compared to 4/16 (25%) on no drug treatment. 
p = 0.JJ29 
6/60 (10%) of all the leiomyomas with no degenerative changes on 
Ieuprolide acetate were associated with dyspareunia compared to 12/71 
(17%) on no drug treatment. 
p = 0.J47J 
2/72 (3%) of all the leiomyomas with non-specific degenerative 
changes on Ieuprolide acetate were associated with dyspareunia compared 
to 9/90 (10%) on no drug treatment. 
p = 0. /JJJ 
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V. TOTAL UTERINE VOLUME 
The total uterine volumes from each MRI study measurements were 
evaluated, and correlated with A/P pain and pressure. 
Abdominal/Pelvic Pain: 
Leuprolide Acetate 
5/36 (14%) of scans with total uterine volume between 0-599.9 cc 
were associated with abdominal/pelvic pain. 
4/12 (33%) of scans with total uterine volume between 600-1 199.9 
cc were associated with abdominal/pelvic pain. 
p = 0.2857 
No Drug Treatment 
14/27 (52%) of scans with total uterine volume between 0-599.9 cc 
were associated with abdominal/pelvic pain. 
8/27 (30%) of scans with total uterine volume between 600-1 199.9 
cc were associated with abdominal/pelvic pain. 
3/8 (38%) of scans with total uterine volume between 1200-1799.9 
cc were associated with abdominal/pelvic pain. 
1/3 (33%) of scans with total uterine volume between 1800-2399.9 
cc were associated with abdominal/pelvic pain. 
0/1 (0%) of scans with total uterine volume between 2400-2999.9 
cc were associated with abdominal/pelvic pain. 
p - 027/6 
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Leuprolide Acetate compared to no drug treatment 
5/36 (14%) of scans with total uterine volume between 0-599.9 cc 
on leuprolide acetate were associated with abdominal/pelvic pain 
compared to 14/27 (52%) on no drug treatment. 
p =0.0015 
4/12 (33%) of scans with total uterine volume between 600-1 199.9 
cc on leuprolide acetate were associated with abdominal/pelvic pain 
compared to 8/27 (30%) on no drug treatment. 
p =0.8851 
Pressure: 
Leuprolide Acetate 
2/36 (6%) of scans with total uterine volume between 0-599.9 cc 
were associated with pressure. 
2/12 (16%) of scans with total uterine volume between 600-1 199.9 
cc were associated with pressure. 
p = 0.5464 
No Drug Treatment 
12/27 (44%) of scans with total uterine volume between 0-599.9 cc 
were associated with pressure. 
8/27 (30%) of scans with total uterine volume between 600-1 199.9 
cc were associated with pressure. 
1/8(13%) of scans with total uterine volume between 1200-1799.9 
cc were associated with pressure. 
0/3 (0%) of scans with total uterine volume between 1800-2399.9 
cc were associated with pressure. 
0/1 (0%) of scans with total uterine volume between 2400-2999.9 

cc were associated with pressure. 
p = 0.2591 
Leuprolide Acetate compared to no drug treatment 
2/36 (6%) of scans with total uterine volume between 0-599.9 cc on 
leuprolide acetate were associated with pressure compared to 12/27 
(44%) on no drug treatment. 
p = 0.0005 
2/12 (16%) of scans with total uterine volume between 600-1199.9 
cc on leuprolide acetate were associated with pressure compared to 3/27 
(30%) on no drug treatment. 
p = 0.6467 
VI. UTERINE NON-LEIOMYOMA VOLUME 
To eliminate errors in analysis that would be introduced because of 
the effect of leuprolide acetate on uterine and leiomyoma volumes, the 
uterine volume measurements from the first MR! study of each patient, 
performed without leuprolide acetate, were used. These were then 
correlated with spontaneous abortion and infertility. 
Spontaneous Abortion: 
2/22 (9%) of patients with uterine non-leiomyoma volume < 500 cc 
had a history of spontaneous abortion. 
1/12 (8%) of patients with uterine non-leiomyoma volume between 
500-999.9 cc had a history of spontaneous abortion. 
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0/2 (0%) of patients with uterine non-leiomyoma volume between 
1000-1499.9 cc had a history of spontaneous abortion. 
p = 09056 
infertility: 
4/22 (15%) of patients 'with uterine non-leiomyoma volume < 500 cc 
had a history of infertility. 
2/12 (17%) of patients with uterine non-leiomyoma volume between 
500-999.9 cc had a history of infertility. 
1/2 (50%) of patients with uterine non-leiomyoma volume between 
1000-1499.9 cc had a history of infertility. 
p = 0529 
VII. TOTAL UTERI ME VOLUME BY BIMANUAL EXAM COMPARED WITH MR! 
CALCULATED VOLUME 
The uterine volume was calculated from each bimanual exam 
estimation, and for each MR! study measurement, as described previously 
in the methods section. This data was then tabulated (Table 2), and 
graphed (fig. 7) to determine any correlation. 
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TABLE 2 Uterine Volumes by MRI measurements and gestational 
size estimates. 
GWK5 EQ MR! UT VOL/CC CALC UT VOL/CC 
17 849.1 1391.6 
9.5 895.3 426.1 
9 61 1.4 386.1 
14 479 915.5 
19.5 981.3 1395.4 
14.5 868.2 985.8 
12.5 872.5 724.7 
16.5 1 1 15.3 1302.9 
16 920.2 1218.1 
12 592 667.5 
18 1219.6 1580.3 
17 818.6 1391.6 
10.5 615.4 514.1 
17.5 414.5 1484.2 
12 444.6 667.5 
r\ 
0 235.9 313.8 
15.5 792.2 1 137.0 
9 254.3 386.1 
18.5 1086.9 1681.5 
8 327.7 j 1 j>.8 
18.5 994.3 1681.5 
“7 / 403.2 251.0 
16.5a 237.4 1302.9 
18 864.6 1580.8 
9 507.7 386.1 
13.5^ 506.6 8-48.6 
6 401.9 197.2 
153 353.3 1059.6 
13 297.2 785.0 
13 244.9 785.0 
5.5 200.8 173.4 
1 3.5° 804.5 843.6 
10 635.9 468.8 
9.5 784.4 426.1 
6 720.2 197.2 
26 2732.2 3740.6 

t n tr 
1 Z.*J 294.3 724.7 
12 362.3 667.5 
15.5 481.7 1 1370 
1 1.5 334.9 613.4 
7 319.4 251.0 
20.5a 789.8 2126.8 
q 364.7 386.1 
7 282.6 251.0 
8 312.2 3:3.8 
8 159.3 TIT fi nJ ! *J.U 
19.5a 802.6 1895.4 
16 944.8 1218.1 
14.5 584.1 985.8 
13.5 993.3 848.6 
19 1430.8 1786.3 
10 6! 1.2 468.8 
1 c: 
1 J 900.4 1059.6 
12 481.3 667.5 
1 1.5a 149.7 613.4 
18 1625.7 1580.8 
12 1014.4 667.5 
17 714.4 1391.6 
15.5 559.1 1 137.0 
8 237.8 313.8 
10 531.9 463.8 
1 1 316 562.3 
16.5 1 090.2 1302.9 
15 377.3 1059.6 
19.5 1 173.3 1895.4 
13.5a 205 5 848.6 
10 474.8 468.8 
13 n 1 70 7- Z i / Z. J i bou.d 
15.5 612.3 1 137.0 
12.5 665.3 724.7 
20.5a 1066.5 2126.8 
15 1 104.2 1059.6 
9.5 313.4 426.1 
8 264.3 313.8 
24 1477.1 3083.4 
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20 857.4 2008.9 
8.5 1077 1681.5 
20 1444.2 2008.9 
20 1350.5 2008.9 
15 1393 1059.6 
9 402.3 386.1 
5.5 385.3 1 7 j.4 
19.5 1350.1 1895.4 
9.5 390 426.1 
o 
0 OpQ O 313.3 
17 588.8 1391.6 
18 1046.7 1580.3 
9 440 386.1 
a Symphysio-fundal height was converted to gestational size in 
weeks (2). 
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Figure 7. Graph demonstrating the correlation 
MR! uterine volumes (cc) with the uterine volumes 
bimanual gestational age estimations. 
y = 197.4 + 0.52x ; r = 0.77, = 0.59. 
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4. D15CU5510N 
Uterine leiomyomas have always been associated with the 
gynecological complications of menorrhagia, metrorrhagia, dysmenorrhea, 
dyspareunia, pressure, abdominal/pelvic pain, infertility and spontaneous 
abortion. Menorrhagia has been variously attributed to leiomyoma 
characteristics, such as submucosal tumor locations with endometrial 
ulceration (9, 29. 42), mechanical interference with the uterine blood 
supply (15, 16), and decreased uterine hemostasis due to the presence of 
intramural tumors (42). More recently, Hricak et al. reported 
hypermenorrhea in all of the 1 1 patients who had disruption of the MR! 
detected junctional zone in her study (27). However, our results show no 
statistically significant correlation between junctional zone disruption 
(which was considered equivalent to the incidence of submucosal 
leiomyomas in our study) and menorrhagia or metrorrhagia. When patients 
with intact junctional zones were examined, the presence of intramural 
leiomyomas was associated with menorrhagia in patients on no drug 
treatment. This supports the theory that impaired uterine hemostasis, 
which occurs as a result of decreased contraction due to the presence of 
intramural leiomyomas, causes the increased bleeding (42). The relative 
insignificance of the presence of submucosal leiomyomas is somewhat 
contradictory to the results of Farber-Brown et al., which implied more of 
a correlation with menorrhagia. However, their studies also confirmed 
that intramural and even subserosal tumors can cause compression of the 
blood vessels predisposing the patient to menorrhagia (15, 16). The most 
significant difference occurred between the LA treated and no drug 
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treatment groups, where LA was clearly effective in decreasing the 
incidence of menorrhagia. This is most likely due to its supressive 
effects on the pituitary-ovarian axis , through its GnRH agonist-antagonist 
actions. Since the patients are rendered arnenorrheic, their menorrhagia is 
effectively eliminated. 
Abdominal/pelvic pain and pressure are also frequent symptoms 
associated with uterine leiomyomas. These are believed to be due to the 
enlarged leiomyornatous uterus impinging on the abdominal/pelvic organs 
and nerves (29, 42) and stretching of pelvic adhesions. We evaluated total 
uterine volume and the symptoms of pain and pressure in each patient, but 
did not find any statistically significant relationship between them. This 
is probably due to the fact that the sensation of pain or pressure is very 
subjective, and depends more on the patients' tolerance levels and the rate 
of growth of the tumor. Carneous leiomyomas were associated with A/P 
pain in patients with no drug treatment. This differs from the results of 
Persaud et al., who found no correlation between A/P pain and the 
degenerative changes of leiomyomas on pathologic examination (45). The 
association of carneous leiomyomas causing acute pain during pregnancy 
has always been generally accepted (42). However, none of these patients 
were pregnant. Treatment with LA decreased the incidence of pain in 
patients with uterine volumes less than 500 cc, but did not have a 
significant effect on the occurence of pain in patients with any type of 
degenerated leiomyomas. This may be due to the fact that uterine volumes 
in patients on LA represent a decrease from larger pretreatment volumes. 
This decrease in uterine size is likely to eliminate, or at least diminish, 
more serious complaints that existed previously - a subjective bias that 
patients on no drug therapy would not exhibit. LA also decreased the 
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incidence of pressure in patients with a dominant leiomyoma in the 
uterine body. The urinary bladder is in close proximity to the body of the 
uterus, and patients are more likely to be sensitive to uterine volume 
changes in this location. 
Dysmenorrhea has been associated with cramping due to intramural 
leiomyomas (42). This was observed in our patient group that did not 
receive any LA. Patients, in both groups, with intramural tumors were 
more likely to have dysmenorrhea than patients with subserosa! and 
submucosal tumors. This increased cramping is probably due to the mass 
of the intramural leiomyomas opposing contraction of the myometrium 
during menses. Dysmenorrhea was again decreased in LA treated patients, 
since they were amenorrheic. Dyspareunia is believed to be more common 
in patients with cervical leiomyomas. Only two patients in our study had 
cervical tumors, and neither patient complained of dyspareunia. This 
number of patients is too small to generate a definite conclusion. The 
effect of LA in decreasing the incidence of dyspareunia when uterine 
volumes were less than 600 cc can also be explained (as above for A/P 
pain) as a subjective feeling of improvement experienced by the patients 
due to the decrease in uterine volume. 
It is generally believed that the location or type of leiomyoma can 
increase the incidence of infertility and spontaneous abortion (9). We did 
not find any statistically significant relationship when we evaluated 
junctional zone disruption, the location, and the type of leiomyoma in 12 
patients with infertility and four patients with spontaneous abortion. We 
also could not find any correlation between uterine non-leiomyoma 
volumes and infertility or spontaneous abortion. Since only about 2-10% of 
infertility problems can be attributed solely to the presence of 

leiomyomas (9, 29), it is not too surprising that we were not able to 
detect any definite relationship in the small patient sample that we 
evaluated. It is, however, interesting that we had so few patients (4/45) 
with a history of spontaneous abortion, since the incidence in women with 
leiomyomas has been reported as high as 41% (9). It would seem logical 
that as a result of decreased intrauterine volume and alteration of the 
normal endometrium caused by the tumors (9), the patients might be more 
prone to spontaneous abortions. However, several women with large 
leiomyomas have had children without difficulty, so there are probably 
other factors to be considered when fertility is being assessed in these 
women. 
We found that the type of degeneration that occurred in leiomyomas 
was dependent on leiomyoma size. Smaller tumors tended to have either no 
degenerative changes or a non-specific degenerative pattern which may 
have been hyaline change, but we could not confirm this with pathologic 
correlation. The larger tumors all had either non-specific or carneous 
degeneration. Hricak et ai. made a similar observation relating the size of 
the tumors to the presence of degeneration (27). This confirms the 
association of degenerative changes with the growth of leiomyomas, 
which causes a decrease in relative blood supply (42). Friedman et ai. 
found a relationship between LA treatment and an increased incidence of 
hyaline degeneration (20), but we did not find any such association with 
any of the tumor degenerative changes that we noted. 
W'e also compared the uterine volumes calculated from estimates of 
gestational week size (17) to those calculated from MR! measurements. 
Since no nomogram of MR! volumes of non-gravid enlarged uteri has been 
constructed yet, we decided to assess how well the estimations from 

pelvic examinations correlated with our MR! volumes. The two uterine 
volumes correlated well, (fig. 7), with a correlation coefficient of 0.77, 
and a coefficient of determination of 0.59. The estimations of gestational 
week size can therefore be reliably predicted from MR! measurements 
about 59% of the time. The 41% variability observed can be explained by 
the fact that the pelvic examinations were performed by several different 
people. Bimanual examinations have always been known to be relatively 
inaccurate and unreliable, depending on the experience level of the 
examiner. We obtained MR! volumes of 372.5 cc and 294.3 cc, both 
corresponding to gestational sizes by examination of 12.5 weeks or 724.7 
cc (Table 2). This further serves to illustrate the marked variation that 
occurs with bimanual estimations of uterine size. The errors introduced by 
the equation used to calculate the MR! uterine volume increase with the 
more irregularly shaped uteri. It is important to be able to accurately 
evaluate uterine volume, since it is often used by clinicians to make 
therapeutic decisions, in patients who are already being evaluated with 
MR!, this additional service could be made available if a standardized 
nomogram were constructed. 
This is the first comprehensive study to examine the MR! 
characteristics of uterine leiomyoma disease, and attempt to correlate 
them with the clinical symptoms of the patients. The only significant MR,- 
clinical correlations occurred between dysmenorrhea and intramural 
tumors, degeneration and tumor size, and LA treated patients and patients 
with no drug treatment. However, it is possible that if future studies were 
to correlate each clinical symptom with more than one characteristic of 
the leiomyomas, more statistically significant associations might be 
found, and we would be closer to understanding the symptomatology of 

uterine leiomyomas. 

66 
5. FIGURES 
Figure la. Sagittal T1 weighted (TR=400J TE=25) images of a normal 
uterus demonstrating demarcation of the uterus OJ) from the surrounding 
fat. No internal uterine anatomy is seen. 

Figure lb. Sagittal T2 weighted (TR=2000, TE=30) images of the normal 
uterus in la. Note the internal uterine anatomy. Endometrial stripe (E), 
Junctional zone (J), Myometrium (M), Endocervical canal (C), Bladder (5). 

68 
Figure 1c, Transverse T2 weighted (TR=2000, TE=30) images of the 
normal uterus in la. Note the internal uterine anatomy. Endometrial stripe 
(E), Junctional zone (J), Myometrium (M). 
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Figure 2. Sagittal T2 weighted (TR-1700. TE=80) image of a subserosa! 
cervical leiomyoma with an increased inhomogeneous interna! signal. 
Endometrial stripe (E), Junctional zone (J), Myometrium (M), Endocervical 
canal (C), Leiomyoma (L), Feeding vessel (arrow). 
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Figure 3. Sagittal 12 (TR=1700, TE=80) weighted image demonstrating 
splaying of the endometrial stripe (E) by two submucosal leiomyomas (L). 
Note the increased signal of degenerative change in the larger leiomyoma 
(arrow). 
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Figure 4. Sagittal T2 weighted (TR= 1800, TE= 80) image demonstrating 
an intramural leiomyoma (ID with a submucosal component disrupting the 
junctional zone (arrow), and a large subserosal leiomyoma (SL) . Note the 
Inhomogeneous increased signal in both leiomyomas. Endometrial stripe 
(E),"junctional zone (J), Myometrium (M). 
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Figure 5. Sagittal T2 weighted (TFM800, TE=60) image of intramural 
leiomyoma (L) with inhomogeneous* increased signal Note the displaced 
uterus and endometrial stripe (E). 

73 
Figure 6. Transverse T2 (TR= 1700., TE= 80) weighted image of a large 
subserosa] leiomyoma (5L) extending into the broad ligament. Note the 
uterus is displaced to the right (U). Also note the intramural leiomyoma 
(!L) with increased signal. 
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